(株)ミズホメディーの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4595/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2021/02/12 | 日証協 | 656,868株 | +0.27% | 58,200株 | +24.36% | 622,077株 | -2.7% | 84,222株 | +72.28% |
2021/02/05 | 日証協 | 655,068株 | +1.1% | 46,800株 | -61.32% | 639,333株 | +1.4% | 48,886株 | -27.04% |
2021/01/29 | 日証協 | 647,968株 | -0.05% | 121,000株 | +67.13% | 630,533株 | -0.25% | 67,000株 | -19.66% |
2021/01/22 | 日証協 | 648,268株 | -0.7% | 72,400株 | +905.56% | 632,133株 | -0.92% | 83,400株 | +644.64% |
2021/01/15 | 日証協 | 652,868株 | -1.66% | 7,200株 | -96.57% | 638,033株 | -0.73% | 11,200株 | -69.23% |
2021/01/08 | 日証協 | 663,868株 | -6.25% | 209,734株 | +456.32% | 642,733株 | +15.38% | 36,400株 | -74.89% |
2020/12/30 | 日証協 | 708,134株 | +0.21% | 37,700株 | -12.93% | 557,057株 | -18.04% | 144,942株 | +184.2% |
2020/12/25 | 日証協 | 706,634株 | -3.5% | 43,300株 | +82.7% | 679,699株 | -0.89% | 51,000株 | +93.59% |
2020/12/18 | 日証協 | 732,234株 | -7.49% | 23,700株 | -77.1% | 685,779株 | -5.43% | 26,345株 | -54.88% |
2020/12/11 | 日証協 | 791,534株 | +5.91% | 103,500株 | -71.65% | 725,174株 | +1.33% | 58,386株 | -55.16% |
2020/12/04 | 日証協 | 747,334株 | +11.5% | 365,100株 | +379.56% | 715,674株 | +7.45% | 130,220株 | +89.22% |
2020/11/27 | 日証協 | 670,234株 | +2.3% | 76,133株 | +89.39% | 666,027株 | +3.53% | 68,820株 | -12.03% |
2020/11/20 | 日証協 | 655,134株 | +0.97% | 40,200株 | -26.32% | 643,305株 | +9.54% | 78,235株 | -16.51% |
2020/11/13 | 日証協 | 648,834株 | -8.08% | 54,560株 | -56.33% | 587,272株 | -5.88% | 93,701株 | +45.27% |
2020/11/06 | 日証協 | 705,834株 | +1.36% | 124,946株 | +227.94% | 623,971株 | +3.98% | 64,500株 | +12.17% |
2020/10/30 | 日証協 | 696,334株 | -2.66% | 38,100株 | -25.13% | 600,071株 | -2.07% | 57,500株 | +140.59% |
2020/10/23 | 日証協 | 715,334株 | +0.76% | 50,886株 | +44.97% | 612,771株 | +0.38% | 23,900株 | -33.43% |
2020/10/16 | 日証協 | 709,934株 | +0.03% | 35,100株 | +91.8% | 610,471株 | -0.21% | 35,900株 | +391.78% |
2020/10/09 | 日証協 | 709,734株 | -4.67% | 18,300株 | -82.65% | 611,771株 | -2.25% | 7,300株 | -89.5% |
※株式分割は考慮していませんのでご注意ください。
Page Top